tetano
Editor, Senior Moderator
Nat Commun
. 2024 Aug 20;15(1):6664.
doi: 10.1038/s41467-024-50339-4. Non-human primate model of long-COVID identifies immune associates of hyperglycemia
Clovis S Palmer[SUP] #[/SUP][SUP] 1 2 [/SUP], Chrysostomos Perdios[SUP] #[/SUP][SUP] 3 4 [/SUP], Mohamed Abdel-Mohsen[SUP] 5 [/SUP], Joseph Mudd[SUP] 3 4 [/SUP], Prasun K Datta[SUP] 3 4 [/SUP], Nicholas J Maness[SUP] 3 4 [/SUP], Gabrielle Lehmicke[SUP] 3 [/SUP], Nadia Golden[SUP] 3 [/SUP], Linh Hellmers[SUP] 3 [/SUP], Carol Coyne[SUP] 3 [/SUP], Kristyn Moore Green[SUP] 3 [/SUP], Cecily Midkiff[SUP] 3 [/SUP], Kelsey Williams[SUP] 3 [/SUP], Rafael Tiburcio[SUP] 6 [/SUP], Marissa Fahlberg[SUP] 3 [/SUP], Kyndal Boykin[SUP] 3 [/SUP], Carys Kenway[SUP] 3 [/SUP], Kasi Russell-Lodrigue[SUP] 3 7 [/SUP], Angela Birnbaum[SUP] 3 [/SUP], Rudolf Bohm[SUP] 8 [/SUP], Robert Blair[SUP] 3 9 [/SUP], Jason P Dufour[SUP] 3 7 [/SUP], Tracy Fischer[SUP] 3 4 [/SUP], Ahmad A Saied[SUP] 3 9 [/SUP], Jay Rappaport[SUP] 10 11 [/SUP]
Affiliations
Hyperglycemia, and exacerbation of pre-existing deficits in glucose metabolism, are manifestations of the post-acute sequelae of SARS-CoV-2. Our understanding of metabolic decline after acute COVID-19 remains unclear due to the lack of animal models. Here, we report a non-human primate model of metabolic post-acute sequelae of SARS-CoV-2 using SARS-CoV-2 infected African green monkeys. Using this model, we identify a dysregulated blood chemokine signature during acute COVID-19 that correlates with elevated and persistent hyperglycemia four months post-infection. Hyperglycemia also correlates with liver glycogen levels, but there is no evidence of substantial long-term SARS-CoV-2 replication in the liver and pancreas. Finally, we report a favorable glycemic effect of the SARS-CoV-2 mRNA vaccine, administered on day 4 post-infection. Together, these data suggest that the African green monkey model exhibits important similarities to humans and can be utilized to assess therapeutic candidates to combat COVID-related metabolic defects.
. 2024 Aug 20;15(1):6664.
doi: 10.1038/s41467-024-50339-4. Non-human primate model of long-COVID identifies immune associates of hyperglycemia
Clovis S Palmer[SUP] #[/SUP][SUP] 1 2 [/SUP], Chrysostomos Perdios[SUP] #[/SUP][SUP] 3 4 [/SUP], Mohamed Abdel-Mohsen[SUP] 5 [/SUP], Joseph Mudd[SUP] 3 4 [/SUP], Prasun K Datta[SUP] 3 4 [/SUP], Nicholas J Maness[SUP] 3 4 [/SUP], Gabrielle Lehmicke[SUP] 3 [/SUP], Nadia Golden[SUP] 3 [/SUP], Linh Hellmers[SUP] 3 [/SUP], Carol Coyne[SUP] 3 [/SUP], Kristyn Moore Green[SUP] 3 [/SUP], Cecily Midkiff[SUP] 3 [/SUP], Kelsey Williams[SUP] 3 [/SUP], Rafael Tiburcio[SUP] 6 [/SUP], Marissa Fahlberg[SUP] 3 [/SUP], Kyndal Boykin[SUP] 3 [/SUP], Carys Kenway[SUP] 3 [/SUP], Kasi Russell-Lodrigue[SUP] 3 7 [/SUP], Angela Birnbaum[SUP] 3 [/SUP], Rudolf Bohm[SUP] 8 [/SUP], Robert Blair[SUP] 3 9 [/SUP], Jason P Dufour[SUP] 3 7 [/SUP], Tracy Fischer[SUP] 3 4 [/SUP], Ahmad A Saied[SUP] 3 9 [/SUP], Jay Rappaport[SUP] 10 11 [/SUP]
Affiliations
- PMID: 39164284
- PMCID: PMC11335872
- DOI: 10.1038/s41467-024-50339-4
Hyperglycemia, and exacerbation of pre-existing deficits in glucose metabolism, are manifestations of the post-acute sequelae of SARS-CoV-2. Our understanding of metabolic decline after acute COVID-19 remains unclear due to the lack of animal models. Here, we report a non-human primate model of metabolic post-acute sequelae of SARS-CoV-2 using SARS-CoV-2 infected African green monkeys. Using this model, we identify a dysregulated blood chemokine signature during acute COVID-19 that correlates with elevated and persistent hyperglycemia four months post-infection. Hyperglycemia also correlates with liver glycogen levels, but there is no evidence of substantial long-term SARS-CoV-2 replication in the liver and pancreas. Finally, we report a favorable glycemic effect of the SARS-CoV-2 mRNA vaccine, administered on day 4 post-infection. Together, these data suggest that the African green monkey model exhibits important similarities to humans and can be utilized to assess therapeutic candidates to combat COVID-related metabolic defects.